General
Preferred name
TASIMELTEON
Synonyms
VEC-162 ()
BMS-214778 ()
BMS 214778, VEC 162 ()
BMS-214,778 ()
Hetlioz ()
HETLIOZ LQ ()
Tasimelteon-d5 ()
P&D ID
PD009143
CAS
609799-22-6
1962124-51-1
Tags
available
drug
Approved by
FDA
First approval
2014
Drug indication
Liver disease
Insomnia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tasimelteon is a melatonin receptor agonist, activating both the MT1 and MT2 receptor subtypes equipotently. and are also melatonin receptor agonist class drugs. (GtoPdb)
DESCRIPTION Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].
PRICE 29
DESCRIPTION Tasimelteon (BMS-214778) is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals. (TargetMol Bioactive Compound Library)
Compound Sets
22
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
245.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
2.25
TPSA
38.33
Fraction CSP3
0.53
Chiral centers
2.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Melatonin Receptor
MT1 receptor
MT2 receptor
MTNR1A, MTNR1B
MT Receptor
Indication
Non-24-Hour Sleep-Wake Disorder
MOA
Melatonin receptor agonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Recommended Cell Concentration
None
Source data